Veraxa to list on Nasdaq through Voyager Acquisition Corp merger

Xlife Sciences (SIX:XLS) says that Veraxa Biotech is to list as a public company on the Nasdaq Global Market through a strategic merger with the special purpose acquisition company Voyager Acquisition Corp.

This proposed business combination would create a publicly-traded, clinical-stage biopharma company focused on the development of a comprehensive pipeline of cancer therapies. Upon closing of the transaction, Veraxa will be listed on Nasdaq under the proposed ticker symbol VERX.

A Switzerland-based biopharma with research and development facilities in Heidelberg, Germany, Veraxa focuses on developing next-generation antibody drug conjugates (ADCs) and bispecific T cell engagers (TCEs).